3 Cash-Producing Stocks We're Skeptical Of

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.

Cash flow is valuable, but it’s not everything - StockStory helps you identify the companies that truly put it to work. Keeping that in mind, here are three cash-producing companies to steer clear of and a few better alternatives.

Semtech (SMTC)

Trailing 12-Month Free Cash Flow Margin: 13.9%

A public company since the late 1960s, Semtech (NASDAQ:SMTC) is a provider of analog and mixed-signal semiconductors used for Internet of Things systems and cloud connectivity.

Why Do We Think SMTC Will Underperform?

1. Mounting operating losses demonstrate the tradeoff between growth and profitability
2. Low free cash flow margin of 9.3% declined over the last five years as its investments ramped, giving it little breathing room
3. Negative returns on capital show management lost money while trying to expand the business, and its shrinking returns suggest its past profit sources are losing steam

At $86.00 per share, Semtech trades at 43.7x forward P/E. If you’re considering SMTC for your portfolio, see our FREE research report to learn more.

RH (RH)

Trailing 12-Month Free Cash Flow Margin: 3.8%

Formerly known as Restoration Hardware, RH (NYSE:RH) is a specialty retailer that exclusively sells its own brand of high-end furniture and home decor.

Why Does RH Fall Short?

1. Disappointing same-store sales over the past two years show customers aren’t responding well to its product selection and store experience
2. Earnings per share have dipped by 38.3% annually over the past three years, which is concerning because stock prices follow EPS over the long term
3. High net-debt-to-EBITDA ratio of 7× increases the risk of forced asset sales or dilutive financing if operational performance weakens

RH is trading at $204.81 per share, or 21.2x forward P/E. Check out our free in-depth research report to learn more about why RH doesn’t pass our bar.

Corcept (CORT)

Trailing 12-Month Free Cash Flow Margin: 22%

Focusing on the powerful stress hormone that affects everything from metabolism to immune function, Corcept Therapeutics (NASDAQ:CORT) develops and markets medications that modulate cortisol to treat endocrine disorders, cancer, and neurological diseases.

Why Do We Think Twice About CORT?

1. Day-to-day expenses have swelled relative to revenue over the last five years as its adjusted operating margin fell by 24.7 percentage points
2. Performance over the past five years shows its incremental sales were much less profitable, as its earnings per share fell by 6.5% annually
3. Free cash flow margin dropped by 21.3 percentage points over the last five years, implying the company became more capital intensive as competition picked up

Corcept’s stock price of $39.97 implies a valuation ratio of 90.2x forward P/E. Read our free research report to see why you should think twice about including CORT in your portfolio.

High-Quality Stocks for All Market Conditions

Your portfolio can’t afford to be based on yesterday’s story. The risk in a handful of heavily crowded stocks is rising daily.

The names generating the next wave of massive growth are right here in our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.